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In vitro formation of advanced glycation end products in
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In vitro formation of advanced glycation end products in peritoneal
dialysis fluid. Glycation of proteins in the peritoneum might occur due to
the extremely high glucose concentrations (75 to 214 mmol/liter) in the
dialysate of patients on continuous ambulatory peritoneal dialysis (CAPD)
and may be involved in the etiology of ultrafiltration failure. Formation of
both early (glycated albumin) and late (advanced glycation end products;
AGE, measured as protein-derived fluorescence intensity, Fl) Maillard
reaction products was studied in vitro in dialysis fluids obtained from seven
patients on CAPD and in phosphate buffered saline (PBS) controls paired
for glucose and albumin concentrations. Percentage glycated albumin
(median, range) increased (P < 0.02) from baseline after 10 and 21 days
in both dialysate and PBS but did not differ (P> 0.05) between the two
media at any time point (day 0, 3.6, 3.1-4.5 vs. 4.1, 3.0-4.6; day 10, 19.4,
7.9-54.8 vs. 19.1, 8.7-50.1; day 21, 29.0, 12.0-75.6 vs. 30.0, 11.7-69.8).
Glycated albumin formation was linearly related to the glucose concen-
tration (r> 0.98, P < 0.001) in both dialysate and PBS at 10 and 21 days.
FT (U/g/liter albumin, median, range) increased (P < 0.02) from baseline
after 10 and 21 days in dialysate but only after 21 days in PBS; this increase
was significantly greater (P < 0.02) in dialysate than in PBS after 10 and
21 days (day 0, 41, 36-46 vs. 42, 37-46; day 10, 99, 88-161 vs. 51, 34-68; day
21, 113, 102-239 vs. 68, 54-91). After 21 days, FT was significantly related
to glucose concentration (r = 0.90,P < 0.01) and to % glycated albumin(r = 0.92, P < 0.01) in PBS but not in dialysate (P > 0.05). AGE
formation, but not glycation, decreased as a function of the dialysate dwell
time and was inhibited by aminoguanidine. Our results demonstrate that
formation of AGE products occurs in dialysis fluid and that factors in
dialysate can modulate this process.
Soluble and structural proteins may undergo condensation
reactions with sugars, predominantly through E-amino groups on
lysine and hydroxylysine residues. These reactions occur in the
absence of enzyme catalysis at a rate related to the protein [1] and
sugar concentrations and the time of exposure of the protein to
that sugar [21. In vivo, glucose is quantitatively the most important
sugar involved in these reactions [3]. The reaction is known as the
Maillard reaction. Initially a ketoamine known as the Amadori
product (glycated protein) is formed. This can undergo a further
series of dehydration and rearrangement reactions to form prod-
ucts known as advanced glycation end (AGE) products. These are
highly insoluble, fluorescent, pigmented polymers which form
inter-molecular cross links [2], even after the initial glucose
stimulus has been removed [4], AGE products are irreversible and
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accumulate over the lifetime of the protein [51. Although the
formation of protein-derived fluorescence may be the result of
glucose-mediated oxidation reactions [6, 7] as well as Maillard
reactions, it is probable that the induction of fluorescence repre-
sents glucose-mediated protein damage. In the present study the
formation of protein-derived fluorescence has been used as a
marker of AGE product formation.
In the clinical setting most interest in these reactions stems
from the demonstration that high levels of early [8] and late [9, 10]
Maillard reaction products can be demonstrated in the blood and
tissues of patients with diabetes mellitus as a consequence of
hyperglycemia. Protein glycation may play an important role in
the development of the long-term complications of diabetes
mellitus [5, 11]. However, these reactions may also occur in other
situations where high glucose concentrations prevail. In particu-
lar, glycation of soluble and structural proteins in the peritoneum
might occur as a result of the extremely high glucose concentra-
tions (75 to 214 mmol/liter) present in the dialysate of patients on
continuous ambulatory peritoneal dialysis (CAPD) and may well
have deleterious consequences [12]. Glycation of peritoneal mem-
brane proteins may be involved in the etiology of ultrafiltration
failure in CAPD.
Similarities can be drawn between the pathological changes
seen irs diabetes mellitus and those in the peritoneal membrane
from patients on CAPD. Basement membrane thickening, which
is the classical hallmark of diabetic vascular disease [13, 14] and
may be caused by glycation and AGE product formation on
structural proteins [15], has also been observed in the basal lamina
of the peritoneal capillaries [16, 171 and the mesothelium [17, 18]
in peritoneal biopsies of CAPD patients. Basement membrane
duplication in non-diabetic uraemic patients occurs after fairly
short periods (2 to 66 months) of CAPD and multiple replication
exceeding five layers may be seen in some subjects after longer
periods [17]. In uremic diabetics, thickening of the peritoneal
capillary basement membrane but not of the mesothelium is
present before commencement of dialysis, but increases with
increasing time on CAPD, and capillary occlusion occurs in some
patients [17].
In diabetes, basement membrane thickening may be associated
with increased capillary permeability to solutes [19]. The influence
of peritoneal basement membrane thickening on the transport of
water and solutes during CAPD is not known, but increased
permeability to glucose is associated with decreased ultrafiltration
due to a lower glucose gradient [20].
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We have previously shown [21] that endogenous glycated
albumin levels in peritoneal dialysis fluid from patients on CAPD
are higher than those in concurrent serum samples, due to either
intraperitoneal glycation or preferential transport across the
peritoneal membrane. In vitro experiments confirmed that glyca-
tion occurred in peritoneal dialysis fluid and at a rate related to
glucose concentration [21]. In CAPD patients the peritoneal
membrane is continually exposed to high glucose concentrations
and pathological effects are more likely to relate to the formation
of late, as opposed to early, Maillard reaction products. In the
present study, in vitro experiments have been designed to study
the formation of early (glycated, Amadori product) and late
(AGE product) Maillard reaction products in peritoneal dialysis
fluid.
Methods
Reagents
Glyco-Gel test kits, containing columns consisting of a 1 ml bed
volume of Glycogel B (immobilized m-aminophenyl boronic acid),
were obtained from Pierce and Warriner (Chester, UK). Chemi-
cals were Analar grade from BDH/Merck Ltd. (Poole, Dorset,
UK), unless specified otherwise. Buffers (equilibration wash
buffer, EWB; elution buffer for the non-glycated fraction, EB-NG;
elution buffer for the glycated fraction, EB-G) were as described
previously [22]. All buffers and columns were stored in the dark at
4°C and were equilibrated to room temperature before use.
Human serum albumin (HSA, A-8763), D-sorbitol (S-1876),
D-glucose (G-8270), aminoguanidine-hemisulphate (A-7009) and
BSA (A-4503) were purchased from the Sigma Chemical Co. Ltd.
(Poole, Dorset, UK). Sterile distilled water and peritoneal dialysis
solutions (Dianeal °") were from Baxter Healthcare Ltd. (Norfolk,
UK). Phosphate buffered saline (PBS, 10 mmol/liter, pH 7.4) [23]
was purchased in tablet form from Oxoid Ltd. (Hampshire, UK)
and reconstituted in sterile distilled water.
Centricon°"-30 microconcentrators and Centriprep°-30, con-
taining a membrane with a 30,000 molecular weight (Mr) cut-off,
were from Amicon Ltd. (Gloucester, UK). Disposable filters
(Minisart, 0.2 Lm) were from Sartorius Ltd. (Surrey, UK).
Fluorescence measurements were made using a Perkin-Elmer
LS-5 luminescence spectrophotometer (Perkin-Elmer Ltd. Bucks,
UK) using glass cuvettes supplied by Sigma (C-0162). Glucose was
measured by a glucose oxidase-peroxidase method (Glu-Cinet;
Sciavo Diagnostics Inc., Wayne, NJ, USA) on an Epos analyzer
(BDH/Merck Ltd.).
Measurement of glycated albumin and soluble protein-
derived fluorescence
One ml of dialysate or PBS (containing approximately 1 mg
HSA) was ultrafiltered (Centricon-30, 2200 g, 16°C, 45 mm) to
remove low Mr compounds. Retained fluid and protein (approx-
imately 20 to 40 'id) was washed twice by repeated ultrafiltration
with two aliquots (2 ml each) of PBS, before recovering the
protein by inverting the microconcentrator and re-centrifuging
(1500 g, room temperature, 5 mm) with two aliquots (150 rl each)
of PBS. Ultrafiltrates were retained and assayed for albumin to
ensure that no albumin loss had occurred. The retentate volume
was diluted to 2 ml with PBS.
Dialysate glycated albumin was determined by affinity chroma-
tography as described previously [21]. Fluorescence was deter-
mined at the excitation and emission maxima (Aexcjtatjon 350 nm,
Aemjssio,, 430 nm, slit widths 10 nm) in duplicate in glass cuvettes
against a PBS blank. Albumin concentration in the samples was
determined by radioimmunoassay [24]. Fluorescence intensity
(Fl) was expressed as arbitrary units/glliter albumin.
Two- and fivefold dilution in PBS of a sample containing 0,48
glliter albumin and having a FT of 154, had FT's (corrected for
dilution and blank) of 142 and 150, respectively, demonstrating
that the protein-derived fluorescence gave a linear response. The
fluorescence spectra of albumin which had been incubated for 21
days in glucose-containing dialysate or PBS were similar. The
fluorescence spectrum of the glass cuvettes alone did not change
over the spectrum studied.
In vitro formation of early and late Maillard reaction products
Effect of peritoneal dialysis fluid on rate of formation. Uremic
ultrafiltrates (50 ml, N = 7, glucose 15 to 93 mmol/liter) were
prepared from dialysates drained from CAPD patients at the end
of a routine dwell time by ultrafiltering (Centriprep 30) to remove
endogenous albumin and molecules of Mr >30,000 but not low
Mr solutes such as glucose. The albumin concentration was
measured to confirm total removal of endogenous albumin.
Ultrafiltrates were buffered to pH 7.4 by the addition of sodium
phosphate buffer to a final concentration of 50 mmol/liter. Bac-
terial growth was inhibited by the addition of NaN3 (0.1%). A
fresh (unused) dialysis fluid (76 mmol/liter glucose) was treated
identically. For each dialysate sample, paired PBS controls were
treated as above and spiked to give glucose concentrations
equivalent to those of each dialysate. All samples were then
spiked with HSA to an approximate concentration of 1 glliter.
PBS with albumin but not glucose added was used as a control.
Solutions were divided into 5 ml aliquots in glass tubes and
incubated at 37°C. Aliquots were removed at 0, 10 and 21 days and
stored at —70°C until analysis. Repeat measurement of glucose at
the end of the experiment ensured that no loss had occurred.
Samples were then thawed, mixed well and glycated albumin and
FT determined. Fl's determined in four uremic ultrafiltrates
incubated for 21 days in the absence of albumin were low (mean
1,3 units) and did not increase significantly from baseline (mean
2.2 units), confirming that the F! of ultrafiltered dialysis fluid itself
did not change in the absence of albumin.
Effect of dwell time on rate of formation of Maillard products.
Uremic ultrafiltrates were prepared from dialysates (initial glu-
cose concentration 126 mmol/liter) removed 0, 2 and 4 hours after
instillation into the peritoneal cavity in patients undergoing
peritoneal equilibration tests as part of their routine clinical
assessment. To obtain sufficient material, two pools were pre-
pared, each containing dialysate from five patients. To eliminate
the effect of differing glucose concentrations, the two and four
hour pools were spiked with glucose to give concentrations
equivalent to those of the 0 hour pool (110 mmol/liter). NaN3
(0.1%) was added and fluids were buffered as before and spiked
with HSA (1 g/liter). Glycated albumin and F! were determined
on 5 ml aliquots which had been either frozen immediately
(—70°C) or incubated at 37°C for nine days.
Aminoguanidine inhibition. Dialysate from a single patient at the
end of a four hour dwell was used to prepare a uremic ultrafiltrate
(60 ml, glucose concentration 65 mmol/liter) which was buffered and
NaN3 (0.1%) added as above followed by NSA (approximately
1 g/liter). Aliquots (10 ml) of this solution (and an equivalent PBS
control) were then placed in glass tubes and spiked to give amino-
guanidine concentrations of 0, 25, 50, 100, 200 and 500 mmol/liter.
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15 Fig. 1. Fonnation of glycated albumin in 7 used
dialysates (A) and their paired phosphate buffered
saline controls (B) following incubation for 10
and 21 days. Glucose concentrations (shown on
the right) are in mmollliter. The dialysis fluid
21 with a glucose concentration of 78 mmol/liter
was fresh (unused) and was not included in the
statistical analysis.
Table 1. Formation of glycated albumin and protein-derived
fluorescence intensity in dialysate and phosphate buffered saline
(PBS) controls
Time
days
Glycated albumin %
Fluorescence intensity
Ulgiliter albumin
Dialysate PBS controls Dialysate PBS controls
0
10
21
3.6 (3.1—4.5)
19.4 (7.9—54.8)
29.0° (12.0—75.6)
4.1 (3.0—4.6)
19.1 (8.7—50.1)
30.0° (11.7—69.8)
41(36—46) 42 (37—46)
99s,b (88—161) 51 (34—68)
113a,b (102—239) 68° (54—91)
Fig. 2. Relationship between % glycated albumin and glucose concentration
in 7 used dialysates (S-•) and their paired phosphate buffered saline controls
(0--a) after 10 and 21 days of incubation. Regression equations are given
in the text. The fresh (unused) dialysis fluid is represented by the boxed
symbol and was not included in the statistical analysis.
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P < 0.02 vs. day 0
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Aliquots (5 ml) were either frozen immediately (—70°C) or incu-
bated at 37°C for 10 days. Glycated albumin and Fl were determined
as before on 0 and 10 day samples.
Statistics
Results were analyzed using parametric or non-parametric
statistics as appropriate. Parametric data were analyzed using the
paired t-test (paired-t) and the Pearson product moment correla-
tion coefficient (r) and standard regression. Non-parametric data
were analyzed using the Wilcoxon's matched-pairs signed-ranks
test (Wilcoxon's). Data were analyzed either manually or using
the Minitab Statistical Package (Minitab Inc., State College, PA,
USA) or Statgraphics Version 4.0 (Statistical Graphics Corp. Inc.,
Rockville, MD, USA).
Results
The percentage of glycated albumin increased significantly from
baseline (day 0) after 10 and 21 days in both dialysate and PBS (P
< 0.02 Wilcoxon's test; Fig. 1 and Table 1). There was no
Glucose, mmol/Iiter
significant difference (P> 0.05 Wilcoxon) between the % glycated
albumin in the dialysate and PBS controls at 0, 10 or 21 days
(Table 1). The formation of glycated albumin was linearly related
to the glucose concentration (mmol/liter) (dialysate % glycated
albumin10 day. = —3.27 + 0.60 glucose, r = 0.99, P < 0.001; dialysate
% glycated albumin21 days = —0.13 + 0.83 glucose, r = 0.99,P <
0.001; PBS % glycated albumin10 days = —0.37 + 0.55 glucose, r =
0.98, P < 0.001; PBS % glycated albumin21 days = 4.13 + 0.75
glucose, r = 0.99,P < 0.001; Fig. 2). The rate of glycated albumin
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formation in a fresh (unused) dialysis fluid was similar to that in
dialysates of equivalent glucose concentration (Fig. 2).
Fl (U/glliter albumin) increased from baseline after 10 and 21
days in dialysate but only after 21 days in PBS (P < 0.02 Wilcoxon;
Fig. 3 and Table 1). This increase was significantly greater in
dialysate than in PBS after 10 and 21 days (P < 0.02 Wilcoxon;
Fig. 3 and Table 1). Fl was significantly related to glucose
concentration in PBS after 21 days (PBS Fl21 days = 46.2 + 0.55
glucose, r = 0.90, P < 0.01) but not after 10 days (r 0.70, P>
0.05), and was not related to glucose concentration in dialysate
after 10 (r = 0.66, P> 0.05) or 21 days (r = 0.58, P> 0.1; Fig. 4).
Formation of protein-derived fluorescence in a fresh (unused)
dialysis fluid was greater than that in used dialysate of equivalent
or higher glucose concentration (Fig. 4).
Fl was not related to % glycated albumin in dialysate after 10
(r = 0.62, P > 0.1) or 21 days (r = 0.60, P > 0.1) but was
significantly related to % glycated albumin in PBS after 10 (r =
0.74, P < 0.05, PBS Fl10 days = 32.1 + 0.67 % glycated albumin)
and 21 days (r = 0.90, P < 0.01, PBS Fl21 days = 42.8 + 0.74 %
glycated albumin; Fig. 5).
HSA incubated in PBS in the absence of glucose contained
3.5%, 2.6% and 1.6% glycated albumin and had a FT of 45.6, 48.6
and 51.3 U/glliter albumin at 0, 10 and 21 days, respectively.
In dialysates taken from patients 0, 2 and 4 hours after
commencing dialysis, formation of protein-derived fluorescence
decreased with increasing dwell time of dialysate, while increases
in glycated albumin were similar irrespective of dwell time (Fig.
6).
The development of protein-derived fluorescence, but not
protein glycation, was inhibited by aminoguanidine at a concen-
tration of 25 mmollliter. At higher concentrations of aminogua-
nidine (>100 mmol/liter), there was a decrease in the amount of
glycated albumin formed (Table 2).
Discussion
Albumin has been used as a model protein to study the early
and late Maillard reaction in vitro in peritoneal dialysis fluid.
Formation of the early glycated Amadori product in both dialy-
sate and PBS was linearly related to glucose concentration, as has
been demonstrated in other in vitro buffered systems [21, 25, 26].
After three weeks of incubation, glycation rates did not differ
between dialysates and their paired PBS controls, suggesting that
dialysis fluid does not contain inhibitors or promoters of the early
Maillard reaction other than glucose.
The development of diabetic complications is more likely to be
related to the formation of late, as opposed to early, products of
the Maillard reaction [5], and these products may be more
relevant to the development of peritoneal pathology. It has been
demonstrated here that protein-derived fluorescence, and hence
probably AGE products, readily forms in vitro in peritoneal
dialysis fluid.
In PBS controls, formation of protein-derived fluorescence was
related to glucose concentration and to the % glycated albumin.
Similarly, Eble, Thorpe and Baynes [4] have shown glucose-
dependent cross linking of ribonuclease A in vitro to be markedly
dependent on glucose concentration. In dialysate, however, de-
spite the strong association between glucose concentration and
early Maillard product formation, formation of AGE products
was not related to either glucose concentration or % glycated
albumin. This suggests that other factors may be important in
AGE product formation in dialysis fluid. This is supported by the
fact that AGE products were formed to a lesser extent in PBS
than in dialysate samples paired for glucose concentration.
Additionally, AGE product formation was greater in either
fresh dialysis fluid or in dialysate which had been removed from
patients immediately after instillation, than in dialysates which
had remained for longer periods in the peritoneal cavity. This
effect cannot be related to pH or glucose concentration since
these factors were controlled. The results suggest either that
dialysis fluid contains a factor (or factors) which promotes AGE
product formation, and that its concentration diminishes during
dialysis, or that the concentration of an inhibitor of the reaction
increases in the dialysate during dialysis.
Clearly, as dialysis progresses so the concentration in dialysate
300
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Fig. 3. Fonnation of protein-derived fluorescence
in 7 used dialysates (A) and their paired
phosphate buffered saline controls (B) following
incubation for 10 and 21 days. Glucose
concentrations (shown on the right) are in
mmol/liter. The dialysis fluid with a glucose
concentration of 78 mmol/liter was fresh
(unused) and was not included in the statistical
analysis.
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Fig. 4. Relationship between fluorescence intensity and glucose concentra-
tion in 7 used dialysates (•; r = 0.58, P > 0.1) and their paired phosphate
buffered saline (PBS) controls (0; r = 0.90, P < 0.01) after 21 days of
incubation. The regression equation for the PBS controls (dashed line) is
given in the text. The fresh (unused) dialysis fluid is represented by the
boxed symbol and was not included in the statistical analysis.
of dialyzable uremic toxins increases. A spectrum of low Mr
guanidino-type compounds, including creatinine, guanidine,
methylguanidine and guanidinosuccinic acid, accumulate in the
serum of patients with chronic renal failure [27] and are readily
cleared across the peritoneal membrane during peritoneal dialysis
[28, 291. Given the structural similarity of these compounds to
aminoguanidine, a known inhibitor of the Maillard reaction (vide
infra), it has been suggested that they may inhibit AGE product
formation in proteins by a similar mechanism [30]. However, none
of the guanidino compounds contain the reactive hydrazine group
found in aminoguanidine and reductive amination of the primary
amino group would require harsh conditions unlikely to occur in
vivo [31]. Indeed, it has recently been shown that methylguanidine
is only 7% as effective as aminoguanidine itt inhibiting AGE
product formation [32]. Although guanidine has been demon-
strated to cause massive reductions in fluorescence generation in
BSA in vitro [33], the concentrations used were 100,000-fold in
excess of those likely to be encountered in dialysate [28].
Urea (200 mmol/liter), a non-guanidino nitrogenous com-
pound, also reduced fluorescence formation in BSA in vitro [33].
This could be either as a consequence of protein denaturation
decreasing its susceptibility to oxidative damage [33] or due to
carbamylation of protein amino or sulphydryl groups [34—36]
interfering with fluorescence generation in protein. Accumulation
of endogenous antioxidants in the dialysate such as ascorbate and
urate [371 could also inhibit formation of protein-derived fluores-
cence resulting from oxidative damage. Therefore, if present in
sufficient quantities, uremic toxins might act as natural inhibitors
of the Maillard reaction, potentially limiting damage to the
peritoneum.
Fresh dialysis fluid may contain 3-deoxyglucosone, a potential
reactant in the late stages of the Maillard reaction [6, 38]. Under
hot acid conditions, glucose undergoes dehydration to form
5-hydroxymethylfurfural [39]. Sterilization of peritoneal dialysis
fluid mimics these conditions [40, 41] and this product has been
found as a spontaneous breakdown product of glucose in dialysate
. S •
9- 6
-o
0 10 20 30 40 50 60 70 80 90 100
% Glycated albumin
Fig. 5. Relationship between fluorescence intensity and % glycated albumin
in 7 used dialysates (•; r = 0.60, P > 0.1) and their paired phosphate
buffered saline (PBS) controls (0, r = 0.90, P < 0.01) after 21 days of
incubation. The regression equation for the PBS controls (dashed line) is
given in the text. The fresh (unused) dialysis fluid is represented by the
boxed symbol and was not included in the statistical analysis.
[42]. 3-Deoxyglucosone has been postulated as an intermediate in
the formation of 5-hydroxymethylfurfural from glucose [43].
These findings may be of particular relevance to ultrafiltration
failure. Although estimates of the importance of ultrafiltration
failure as a cause of morbidity in CAPD patients varies greatly
between studies, after peritonitis it is the single major cause of
failure of CAPD [44, 451 and subclinical loss of ultrafiltration is
likely to be even more common [46]. Diminishing ultrafiltration is
often treated by increased use of more hypertonic solutions [47]
and/or decreased dwell times [48]. This will increase exposure of
the peritoneum to glucose and the time during which conditions
favoring AGE product formation pertain, that is, increase the
amount of time during which potential promoters of the reaction
are abundant and/or decrease the time during which inhibitors of
the reaction are present. Hence, if AGE product formation is
important, therapeutic interventions currently used in ultrafiltra-
tion failure may be self-limiting.
Should the Maillard reaction prove to be relevant to the
etiology of ultrafiltration failure, it may be possible to include
inhibitors of the reaction in the dialysis fluid. In an in vitro model
it has been shown that low concentrations of aminoguanidine (25
mmol/liter) inhibit AGE formation with no appreciable effect on
glycated albumin formation, while high concentrations (>100
mmol/liter) affected both early and late Maillard reactions.
The mechanism of action of aminoguanidine is uncertain:
Khatami et al [49] observed apparent inhibition of Amadori
product formation at relatively low concentrations of aminogua-
nidine (5 to 50 mmol/Iiter), and suggested that the major action of
aminoguanidine is to inhibit the formation of Amadori product by
competing with protein for free open-chain glucose. Although this
could explain the observed decrease in glycated albumin formed
at high concentrations of aminoguanidine in the present study, it
is not consistent with the results at low concentrations. It seems
likely that the major effect of aminoguanidine in the study of
Khatami et al [49] was to inhibit the reaction of protein with a
fast-reacting contaminant of their radioactive glucose preparation
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Length of incubation at 370
Fluorescence
intensity U/g/liter
.
Aminoguanidine
Glycated albumin % albumin
mmol/liter 0 days 10 days 0 days 10 days
0 3.1 19.4 45 87
25 3.7 20.4 41 46
50 3.7 20.2 49 48
100 3.1 19.0 43 45
200 3.1 16.6 48 45
500 3.1 12.7 41 43
[501; the effect of aminoguanidine on Amadori product formation
was probably minimal.
This present study is consistent with a post-Amadori effect.
Aminoguanidine contains a nucleophilic hydrazine group which
will attack the electron-deficient carbonyl carbon. Both triazine
and dihydrazone products have been isolated following the reac-
tion of one or two aminoguanidine molecules, respectively, with
an Amadori product [511. Brownlee et al [52] suggested that by
blocking the reactive carbonyl groups on the ketoamine, amin-
oguanidine prevented cross-link formation. Additionally, dicar-
bonyl compounds such as 3-deoxyglucosone, which have been
implicated in the formation of AGE products [6, 38], have two
such carbonyl groups and aminoguanidine may trap these inter-
mediate compounds [531. Alternatively, it may inhibit fluores-
cence generation derived from lipid peroxidation products [33],
The present study cannot distinguish between these potential
mechanisms.
We have demonstrated for the first time that formation of AGE
products occurs in dialysis fluid and that factors in dialysate may
modulate this process. Although the number of patients studied is
small, the difference between patient samples and control solu-
tions is unequivocal. The possibility that fresh dialysis fluid may
contain promotors of this reaction needs investigation given its
potential pathological consequences. Similarly, the possibility that
potent naturally occurring inhibitors of the advanced glycation
reaction may occur in vivo is important, both from a physiological
and a pharmacological viewpoint. Our observations have been
made in in vitro studies but, by analogy with diabetes mellitus, it is
likely that they are of clinical relevance.
It is unlikely that glycation and subsequent AGE product
formation on peritoneal structural proteins would be the sole
cause of ultrafiltration failure in CAPD patients. Nevertheless it
may be an important component of this pathological process. For
example, it has recently been suggested that peritonitis (itself a
major cause of ultrafiltration failure) may interact with glycation
in the development of peritoneal structural lesions: demesotheli-
alization during peritonitis may expose the underlying stroma to
extremely high glucose concentrations [12, 54]. Future studies
need to establish the degree of glycation and AGE product
formation occurring on the peritoneal membrane itself during
treatment with CAPD.
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